Phreesia Faces Class Action Lawsuit; Investors Encouraged to Claim Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, reflecting significant dissatisfaction with the company's financial transparency.
- Allegation Details: The complaint alleges that the company and its executives violated federal securities laws by failing to disclose the true state of slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to a loss of investor confidence.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal year 2027 revenue guidance down to $510 million to $520 million, a reduction of $35 million to $49 million from the previous range of $545 million to $559 million, indicating a decline in market demand.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock plummeted by 21% to 28%, demonstrating extreme investor concern regarding the company's future prospects, which may prompt more investors to seek legal recourse.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.380
Low
24.00
Averages
29.09
High
35.00
Current: 9.380
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, reflecting significant dissatisfaction with the company's financial transparency.
- Allegation Details: The complaint alleges that the company and its executives violated federal securities laws by failing to disclose the true state of slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to a loss of investor confidence.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal year 2027 revenue guidance down to $510 million to $520 million, a reduction of $35 million to $49 million from the previous range of $545 million to $559 million, indicating a decline in market demand.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock plummeted by 21% to 28%, demonstrating extreme investor concern regarding the company's future prospects, which may prompt more investors to seek legal recourse.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. faces a class action for allegedly misleading investors about its long-term growth outlook during the period from May 8, 2025, to March 30, 2026, putting its 2027 revenue target at risk, with a lead plaintiff deadline of July 13, 2026.
- Sportradar Allegations: Sportradar Group AG is accused of collaborating with black-market gambling operators and failing to disclose deficiencies in its compliance processes during the class period from November 7, 2024, to April 21, 2026, with a lead plaintiff deadline of July 17, 2026.
- Commvault Issues: Commvault Systems Inc. is facing a lawsuit for not accurately assessing the impact of sales types on its annual recurring revenue growth from April 29, 2025, to January 26, 2026, requiring lead plaintiff motions by July 17, 2026.
- Veritone Financial Misconduct: Veritone, Inc. is under scrutiny for misrecording revenue and costs, necessitating a restatement of financial statements during the class period from October 14, 2025, to April 14, 2026, with a lead plaintiff deadline of July 20, 2026.
See More
Commvault Systems Under Shareholder Investigation for Alleged Misconduct
- Shareholder Investigation Initiated: Grabar Law Office is investigating Commvault Systems, Inc. (NASDAQ: CVLT) for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through its executives' materially false and misleading statements regarding the true state of its projected ARR growth for fiscal year 2026, leading to investor misconceptions about the company's prospects.
- Negative Market Reaction: The failure to accurately reflect crucial variables in the ARR growth environment has resulted in a significant overstatement of Commvault's financial strength and growth prospects, with investors experiencing multiple financial guidance downgrades between 2024 and 2025.
- Potential Legal Consequences: Should the investigation confirm executive misconduct, the company may face legal liabilities and financial losses, adversely affecting its market reputation and future financing capabilities.
See More
Phreesia Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Phreesia, alleging violations of federal securities laws on behalf of all investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026.
- Allegations: The complaint claims that Phreesia failed to disclose slowing demand and reduced visibility into key revenue streams, resulting in materially false and misleading statements regarding the company's business and prospects throughout the class period.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by July 13, 2026, allowing them to share in any potential recovery, with participation in the lawsuit not requiring lead plaintiff status.
- Law Firm Advantage: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, providing risk-free legal representation for investors, and has successfully recovered hundreds of millions for investors nationwide, showcasing its expertise in securities fraud class actions.
See More
Investigation into Phreesia Securities Fraud Lawsuit
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating Phreesia, Inc. for allegedly making false and misleading statements to investors between May 8, 2025, and March 30, 2026, causing them to purchase securities at artificially inflated prices.
- Significant Stock Decline: On March 30, 2026, Phreesia announced a substantial reduction in its revenue growth projections for fiscal year 2027, resulting in a stock price drop from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market pessimism about the company's future prospects.
- Investor Losses: The company's failure to disclose critical negative information led investors to be unaware of Phreesia's slowing demand and reduced visibility in key revenue streams, resulting in significant financial losses for shareholders.
- Opportunity to Participate in Lawsuit: Eligible investors can apply to be lead plaintiffs in the class action lawsuit by July 13, 2026, and Faruqi & Faruqi encourages anyone with relevant information to contact them to support affected investors.
See More
Phreesia Class Action Lawsuit Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, that they must apply to be lead plaintiff by July 13, 2026, or risk losing their right to compensation.
- Fee Arrangement: Investors can participate in the lawsuit without any upfront costs, as the law firm operates on a contingency fee basis, which lowers the financial barrier for investors seeking compensation and encourages broader participation in the class action.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments, which led to investor losses when the truth emerged, indicating a significant trust issue for the company in the market.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its extensive experience and success in handling such cases.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, reflecting significant dissatisfaction with the company's financial transparency.
- Allegation Details: The complaint alleges that the company and its executives violated federal securities laws by failing to disclose the true state of slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to a loss of investor confidence.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal year 2027 revenue guidance down to $510 million to $520 million, a reduction of $35 million to $49 million from the previous range of $545 million to $559 million, indicating a decline in market demand.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock plummeted by 21% to 28%, demonstrating extreme investor concern regarding the company's future prospects, which may prompt more investors to seek legal recourse.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. faces a class action for allegedly misleading investors about its long-term growth outlook during the period from May 8, 2025, to March 30, 2026, putting its 2027 revenue target at risk, with a lead plaintiff deadline of July 13, 2026.
- Sportradar Allegations: Sportradar Group AG is accused of collaborating with black-market gambling operators and failing to disclose deficiencies in its compliance processes during the class period from November 7, 2024, to April 21, 2026, with a lead plaintiff deadline of July 17, 2026.
- Commvault Issues: Commvault Systems Inc. is facing a lawsuit for not accurately assessing the impact of sales types on its annual recurring revenue growth from April 29, 2025, to January 26, 2026, requiring lead plaintiff motions by July 17, 2026.
- Veritone Financial Misconduct: Veritone, Inc. is under scrutiny for misrecording revenue and costs, necessitating a restatement of financial statements during the class period from October 14, 2025, to April 14, 2026, with a lead plaintiff deadline of July 20, 2026.
See More
Commvault Systems Under Shareholder Investigation for Alleged Misconduct
- Shareholder Investigation Initiated: Grabar Law Office is investigating Commvault Systems, Inc. (NASDAQ: CVLT) for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased shares before April 29, 2025, to seek corporate reforms and fund recovery.
- Allegations of False Statements: A recently filed securities fraud class action alleges that Commvault misled investors through its executives' materially false and misleading statements regarding the true state of its projected ARR growth for fiscal year 2026, leading to investor misconceptions about the company's prospects.
- Negative Market Reaction: The failure to accurately reflect crucial variables in the ARR growth environment has resulted in a significant overstatement of Commvault's financial strength and growth prospects, with investors experiencing multiple financial guidance downgrades between 2024 and 2025.
- Potential Legal Consequences: Should the investigation confirm executive misconduct, the company may face legal liabilities and financial losses, adversely affecting its market reputation and future financing capabilities.
See More
Phreesia Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Phreesia, alleging violations of federal securities laws on behalf of all investors who purchased Phreesia securities between May 8, 2025, and March 30, 2026.
- Allegations: The complaint claims that Phreesia failed to disclose slowing demand and reduced visibility into key revenue streams, resulting in materially false and misleading statements regarding the company's business and prospects throughout the class period.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by July 13, 2026, allowing them to share in any potential recovery, with participation in the lawsuit not requiring lead plaintiff status.
- Law Firm Advantage: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, providing risk-free legal representation for investors, and has successfully recovered hundreds of millions for investors nationwide, showcasing its expertise in securities fraud class actions.
See More
Investigation into Phreesia Securities Fraud Lawsuit
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating Phreesia, Inc. for allegedly making false and misleading statements to investors between May 8, 2025, and March 30, 2026, causing them to purchase securities at artificially inflated prices.
- Significant Stock Decline: On March 30, 2026, Phreesia announced a substantial reduction in its revenue growth projections for fiscal year 2027, resulting in a stock price drop from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market pessimism about the company's future prospects.
- Investor Losses: The company's failure to disclose critical negative information led investors to be unaware of Phreesia's slowing demand and reduced visibility in key revenue streams, resulting in significant financial losses for shareholders.
- Opportunity to Participate in Lawsuit: Eligible investors can apply to be lead plaintiffs in the class action lawsuit by July 13, 2026, and Faruqi & Faruqi encourages anyone with relevant information to contact them to support affected investors.
See More
Phreesia Class Action Lawsuit Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, that they must apply to be lead plaintiff by July 13, 2026, or risk losing their right to compensation.
- Fee Arrangement: Investors can participate in the lawsuit without any upfront costs, as the law firm operates on a contingency fee basis, which lowers the financial barrier for investors seeking compensation and encourages broader participation in the class action.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments, which led to investor losses when the truth emerged, indicating a significant trust issue for the company in the market.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its extensive experience and success in handling such cases.
See More
